Pipeline
Antibody
EU103
| Indication Solid tumor | Target /Drug class Anti-human VSIG4 mAb | Development Stage Non-clinical |
Summary
- Humanized monoclonal antibody of the engineered IgG1/kappa
- Immunotherapeutic, anti-human VSIG4 antibody
- Regulator of macrophage differentiation : regulator of typeⅡ macrophage conversion
- Blockade of inhibition of cytotoxic T cell
In vitro/in vivo Efficacy
Mode of Action
-
-
1 Induces CD＋ T cell proliferation for enhanced cytotoxicity
2 Converts suppressive M2 to M1 macrophage for inprovement of tumor microenvironment